The treatment options for metastatic renal cell carcinoma (RCC) have changed considerably over the past 10 years with the introduction of immunotherapies, such as nivolumab, ipilimumab and pembrolizumab. However, with the new treatments comes the challenge of selecting the most effective treatment for each individual patient. Clinicians are constantly looking for ways to discover which […]
This paper reviews the use of stereotactic body radiotherapy (SBRT) for the treatment of renal cell carcinoma (RCC), and was presented at the Society of Urologic Oncology (SUO) in Washington last week. In conclusion: RCC is radiosensitive and SBRT can be used to stabilise or manage the symptoms of primary tumours SBRT may be useful […]
A recent study published in European Urology Oncology this month looked at the impact of tumour size on survival in patients with metastatic renal cell carcinoma (RCC) who had had surgery to remove their tumour. The researchers interrogated two databases from America, looking at tumour size and overall survival. Data from over 1,000 patients were […]
Two recent studies have looked at the effect of stereotactic body radiotherapy (SBRT) in combination with tyrosine kinase inhibitors or immune checkpoint inhibitors on renal cell carcinoma (RCC) metastases and survival. In the first study, a total of 17 patients with stable metastatic RCC were assessed. The effect of SBRT on the target metastasis was […]
Interim results from an ongoing clinical trial of lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma (RCC) who have already received an immune checkpoint inhibitor. The trial included up to 360 patients with various cancers, of which 33 patients had metastatic clear cell RCC. The patients took a […]
Two small studies looked at the addition of a type of radiotherapy treatment, called stereotactic body radiotherapy (SBRT), to treatment with a tyrosine kinase inhibitor (TKI), such as sunitinib or pazopanib, or a checkpoint inhibitor, such as nivolumab for patients with metastatic renal cell carcinoma (RCC). In the first study, 56 patients with metastatic RCC […]
This interview with Dr Monty Pal, Associate Professor from the City of Hope National Medical Center in California, USA discusses tumour shrinkage in patients who did not have a nephrectomy. The interview was conducted at the European Society of Medical Oncology (ESMO) 2019 conference in Barcelona earlier this month. Dr Pal discusses the results from […]
A potential treatment for a selected group of patients with metastatic renal cell carcinoma (RCC) is nephrectomy followed by surgery to remove metastases (radical metastasectomy). After surgery, patients are usually followed by observation or treated with anti-cancer drugs. The RESORT clinical trial assessed the potential benefit of treatment with sorafenib after radical metastasectomy compared with […]
This real world study reports on the long term survival of patients with metastatic renal cell carcinoma (RCC) who have taken 1 to 4 lines of systemic drug treatment sequentially under real life conditions. Patients were treated according to their prognostic score (good, intermediate, poor). Overall survival was 57 months in patients with good or intermediate […]
A recent study, published in Clinical Genitourinary Cancer, looked at the clinical features, treatment outcomes and genetic profiles of patients with mucinous tubular and spindle-cell carcinoma (MTSCC), a rare type of kidney cancer. There were 25 patients in the study, most of which had asymptomatic low-grade and localised tumours. Six patients had metastatic disease. The […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
